Navigation Links
Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
Date:2/11/2008

- Over 1,500 U.S. patients enrolled in study examining potential new

'GI-friendly' treatment for mild to moderate pain -

- Clinical results expected in second half of 2008 -

PALO ALTO, Calif., Feb. 11 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that it is closing enrollment in its two phase 3 trials HZ-CA-301 and HZ-CA-303 for its lead product candidate HZT-501, an investigational prescription NSAID (non-steroidal anti-inflammatory drug) designed to be "GI-friendly".

"We enrolled over fifteen hundred patients in less than a year, which was well ahead of our projections," said George F. Tidmarsh, M.D., Ph.D., co-founder and chief executive officer of Horizon Therapeutics. "We look forward to receiving the complete set of clinical results and safety data to review this Fall."

The Phase 3 program is comprised of two trials involving a total of 1,500 patients with mild-to-moderate pain, including patients with osteoarthritis. Horizon Protocol HZ-CA-301 and HZ-CA-303 are evaluating the efficacy and safety of HZT-501 with a primary endpoint of reduction in the risk of development of ibuprofen-associated upper gastrointestinal (gastric and/or duodenal) ulcers in patients who require the use of ibuprofen.

The clinical trials are multi-center, randomized, controlled, and blinded for up to 24 weeks of treatment, followed by a 4 week safety evaluation period. The studies are being conducted in the United States.

"The Horizon studies are among the largest endoscopic trials ever conducted regarding NSAID-induced gastrointestinal ulcers," said Loren Laine M.D., professor of medicine in the Division of Gastrointestinal and Liver Diseases, University of Southern California. "The results should provide precise estimates of the potential benefit of HZT-501 in decreasing NSAID-associated ulcers."

In addition, a phase 3 follow-on safety study HZ-CA-30
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
2. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... – Small Cap IR issues report. Recently, Arrayit Corporation ... blood card technology to Vivos, Global Genome Vault, the ... an impervious, impenetrable and permanent DNA storage vault, able ... Earth, a safe and secure nuclear blast-proof, underground shelter ... rapid collection, separation, drying and storage of human genomic ...
(Date:6/30/2015)... N.C. , June 30, 2015  Marken, the ... to the life sciences industry, has been granted permission ... patient shipment of clinical drug product in Korea.  This ... South Korea to continue receiving their clinical ... System (MERS). The emergency was caused by ...
(Date:6/30/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... of StockholdersWhen:Tuesday, June 30 at 5:10 p.m. ET / ... log onto our website listed above.   ... event, a replay of the webcast will be available ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 2Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 3
... Feb. 23 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical trial of Unit Dose Budesonide (UDB) ... The Company announced that the clinical,trial did not ... by,changes from baseline in nighttime and daytime composite ...
... BCRX ) today announced that the full ... peramivir in patients hospitalized for influenza was presented by ... Professor, Divisions of Infectious Diseases and Organ Transplantation at ... the XI International Symposium on Respiratory Viral Infections taking ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 2Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 4Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 5
(Date:6/30/2015)... ... 30, 2015 , ... University Post-Acute Rehab recently released a ... rehab center’s patients and their experiences at the facility. Medicare granted University Post-Acute ... Each patient attests to the high rating, which is predominantly based on cleanliness, ...
(Date:6/30/2015)... ... 2015 , ... According to a June 15th report from USC ... sensory stimuli can be used to “decrease children’s anxiety and negative responses during oral ... will compare patient experience in a “typical dental environment” with one that provides “visual, ...
(Date:6/30/2015)... ... 30, 2015 , ... Broadway by the Sea posted its newest YouTube video ... testimonials. Medicare rated the care center as a five-star location based on a comprehensive ... future patients a firsthand look at the facility’s satisfied residents. , “In this ...
(Date:6/30/2015)... ... June 30, 2015 , ... After many requests from ... its here, http://www.express-glasses.com is proud to announce its collaboration with DHL ... shipping with DHL Express when calling or visiting the express glasses website. express ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... a federal multidistrict litigation now underway in the U.S. District Court, Eastern District ... Conference. According to the Court’s calendar, that conference has now been scheduled for ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3
... November 2, 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 28 The goal of ... Paul Angulo, was to determine the,effects of fatty liver disease ... is especially important as nonalcoholic fatty liver disease,(NAFLD) is the ...
... 28 CoLucid Pharmaceuticals, Inc., an,innovative biotechnology ... disorders, announced today that it has appointed ... In this position, Hogan will apply more,than ... and biopharmaceutical,industries to drive CoLucid,s business development ...
... WOBURN, Mass., Oct. 28 Galenea Corp.,today announced ... and its,academic collaborators that gives Galenea a license ... other related disorders. The license grants,Galenea the exclusive ... indole-based agonists., The licensed compounds have demonstrated ...
... Brain Injury Association (CALBIA), a non-profit membership ... those affected by brain injury, together with the ... representing individuals sustaining traumatic brain injury , ... nation’s most important professional medical/legal conferences dealing with ...
... hemoglobin A1c monitoring market is forecast to surpass $272 million by ... population. Other growth drivers include greater glucose control and product innovations ... ... Jose, CA (PRWEB) October 28, 2008 -- World Health Organization forecasts ...
... you,re an individual watching the stock market crash or ... in the journal Psychological Science, examines how ... their behavior more than young adults when under stress ... looked at how stress affects decision making, even though ...
Cached Medicine News:Health News:Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 2Health News:CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development 2Health News:CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development 3Health News:Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity 2Health News:Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity 3Health News:California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008 2Health News:California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008 3Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:Stress affects older adults more than young adults 2
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
This revolutionary system combines the CSZ Head Wrap and Patient Vest for a non-invasive whole body hypothermia system. This method of cooling the patient allows for early treatment that is fast, cos...
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Medicine Products: